DT2216 decreased tumor BCL-XL levels in xenograft models and to a lesser degree in syngeneic models (Supplementary Fig. 11d–k), which may, in part, explain reduced tumor growth inhibition in the syngeneic experiments. The gene discussed is BCL2L1; the disease is neoplasm.